We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 2.86% | 18.00 | 17.50 | 18.50 | 18.00 | 17.50 | 17.50 | 242,114 | 11:30:47 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.34 | 16.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/11/2016 17:22 | If you look on lse board comments there's a number of them that say they have tried a number of times to get stock and failed. | riskybusiness1 | |
28/11/2016 17:19 | Saying their is no mn involved is calling opti management a bunch of frauds. Looking at aim as a whole this is possible. Looking at this managements track record you realise that's a very stupid assumption. As clearly mentioned by management their are a number of partners involved 'some mn'. If one is not announced between now n spring it will be because the terms do not suit opti going forward. | riskybusiness1 | |
28/11/2016 17:06 | Parob 3X 2 LSE. 1 Isdx | john henry | |
28/11/2016 16:54 | Thats my interpretation, Parob. | luminoso | |
28/11/2016 16:42 | Although it is preferable to have an mn on board and I don't believe it's possible to call it either way yet, isn't the more important aspect here that we are looking at a probable spring launch( hopefully sooner) of revenue generating products? | 1bokke | |
28/11/2016 16:32 | Elrico, happy to proven wrong but very much doubt it. Let's see what happens in April. | mazzstar | |
28/11/2016 16:29 | Mazz - wrong! | elrico | |
28/11/2016 16:25 | 2 X 25K buys just gone through. Are we being dropped to this level deliberately to let an insti in? Know this has been mentioned here before... | parob | |
28/11/2016 16:20 | JH, doesn't take a genuis to work out there is no MN from reading last month's RNS. | mazzstar | |
28/11/2016 16:16 | Even if there isn't a MN on-board right away (I still think there will be)...this could actually turn out to be of great benefit. These cholesterol reducing supplement seems to be dirt cheap to produce and will no doubt be sold at a massive premium. If OPTI are going in alone it means far more profit (more risk too admittedly) As mentioned before by someone...I believe the products launch will be met with quite a fan-fair and could garner a lot of press attention. This won't be 'just another' weight loss product (like Go-Figure) it will be the saviour for huge numbers of people that use Statins. Remember that hard science journals will also be released early next year...effectively giving the thumbs up to our products. | f3rdinand | |
28/11/2016 16:00 | Mazzstar I think most investors have pretty much concluded that there is no MN involved. | john henry | |
28/11/2016 15:22 | DAFAD - Not sure if you is playing dafd :-) GoFigure launched June 2016. | elrico | |
28/11/2016 15:21 | Reading the 26/10 RNS and SOH saying last week he is "confident there WILL be deals" is all pointing to a self funded launch in April with 'partners' more likely to be Revital and Holland & Barrett. No MNs on board yet I'm afraid. Hopefully skin will change that next year. | mazzstar | |
28/11/2016 15:16 | Ironman: Investor Chronicle 1 Feb 2016. Mazzstar, as you like. Be lucky all with patience | parsnip1 | |
28/11/2016 15:09 | would the new year not be a good time to launch a weight reducing/slimming product?? | dafad | |
28/11/2016 15:05 | SOH's comments add weight to the hypothesis a cardiovascular deal has been signed off, but with which MN(S)? SOH is talking in present tense when he talks about OPTI products. "OptiBiotix products work by different mechanism of action to statins and will provide a range of cardiovascular products to reduce both LDL cholesterol and blood pressure, two factors known to increase cardiovascular risk. These products have the potential to provide a safe alternative or supplement to existing options to reduce cardiovascular risk". I think it is safe to assume these are anticipated to be on the shelves by spring 2017. | elrico | |
28/11/2016 14:58 | I would take SOH's earlier comments in the year with a massive pinch of salt. | mazzstar | |
28/11/2016 14:48 | Parsnip, when/where did he indicate that if you don't mind me asking? | ironman22 | |
28/11/2016 14:20 | The CEO indicated many months ago the share price should be circa £2 based on the then current (intangible) assets. That was without any forward order book. From all verbal indications TW3. Let us relax | parsnip1 | |
28/11/2016 14:20 | The CEO indicated many months ago the share price should be circa £2 based on the then current (intangible) assets. That was without any forward order book. From all verbal indications TW3. Let us relax | parsnip1 | |
28/11/2016 12:38 | Placing sells are indiscriminate with what is happening in the company. The good thing here is that Opti are fully funded and their revenue streams are starting and about to grow.. | bobdown2 | |
28/11/2016 12:32 | Why sell now though? Unless you think its all a sham, which I don't. Hope we see buyers taking the stock up soon. We have an exiting few months ahead of us according to recent RNS's and SOH. | rafboy | |
28/11/2016 12:28 | Not new. It's been going on for months..it's like there was a placing at a lower price.. | bobdown2 | |
28/11/2016 12:28 | John H - thanks for letting us know - appreciated ;0) | spike_1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions